Draganfly, Doodle Labs, and UXV Technologies Collaborate to Enhance UAV Communication Solutions
April 22, 2024 07:30 ET
|
Draganfly Inc
Innovative Collaboration Between Draganfly, Doodle Labs, and UXV Technologies Sets New Standards for UAV Operations San Diego, CA., April 22, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ:...
Fleetio Wins Third Consecutive Sales & Customer Service Stevie® Award
April 17, 2024 09:00 ET
|
Fleetio
BIRMINGHAM, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Fleetio, the leading fleet maintenance management software company, today announced it has won a 2024 Silver Stevie® Sales & Customer Service...
SupplyCore Inc. Awarded Fire and Emergency Services Equipment (F&ESE) Contract by Defense Logistics Agency
April 10, 2024 11:00 ET
|
SupplyCore Inc.
Rockford, Illinois, April 10, 2024 (GLOBE NEWSWIRE) -- SupplyCore, a supply chain integrator and small business federal defense contractor, has been awarded a contract for the Fire and Emergency...
Micron Technology, Inc. Reports Results for the First Quarter of Fiscal 2024
December 20, 2023 16:04 ET
|
Micron Technology, Inc.
BOISE, Idaho, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) today announced results for its first quarter of fiscal 2024, which ended November 30, 2023. Fiscal Q1 2024...
New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY®▼ (talquetamab) in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
December 12, 2023 03:00 ET
|
Janssen Pharmaceutica NV
Analysis from MonumenTAL-1 study showed patients with relapsed or refractory multiple myeloma treated with talquetamab were subsequently treated effectively with several classes of therapy, including...
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
December 11, 2023 20:15 ET
|
Harpoon Therapeutics Inc.
• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure...
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
December 11, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of...
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
December 10, 2023 12:30 ET
|
Regeneron Pharmaceuticals, Inc.
Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort...
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
December 07, 2023 01:35 ET
|
Sanofi - Aventis Groupe
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant Sarclisa added to bortezomib,...
Itronics Rock Kleen Secures Representative Agent in Australasia – Provides Solution to Growing Sand Scarcity
December 05, 2023 06:30 ET
|
Itronics Inc.
RENO, NV, Dec. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Itronics Inc. (OTC: ITRO) a “Cleantech Materials” growth Company that manufactures GOLD’n GRO Multi-Nutrient Fertilizers and produces...